Islet transplantation for diabetes treatment requires immunosuppression to control rejection. A microgel presenting Fas ligand with immunomodulatory properties is now shown to prolong the survival of allogeneic islet grafts in vivo.
- Devon M. Headen
- Kyle B. Woodward
- Haval Shirwan
